SCHEMBL5714697

SCHEMBL5714697

Cc1cccc(CCCN2CCN(C(=O)Oc3ccc(CCOc4ccncc4)cc3)CC2)n1

nearest known ligand 0.52

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HRH2 P25021 9/20 0.52
HRH1 P35367 9/20 0.52
ADORA3 P0DMS8 1/20 0.49
HTR2A P28223 1/20 0.49
HTR7 P34969 1/20 0.49
OPRM1 P35372 1/20 0.49
SIGMAR1 Q99720 1/20 0.49
THRB P10828 2/20 0.48
POLB P06746 2/20 0.47
HRH3 Q9Y5N1 2/20 0.43
DRD3 P35462 1/20 0.43
CYP1A2 P05177 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
FAAH O00519 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5714720 0.95 THRB (0.49) HRH2HRH1ADORA3HTR2AHTR7
SCHEMBL5714855 0.91 DRD2 (0.47) HRH2HRH1ADORA3HTR2AHTR7
SCHEMBL5714932 0.90 HRH2 (0.45) HRH2HRH1ADORA3HTR2AHTR7
SCHEMBL5715363 0.88 SIGMAR1 (0.44) HRH2HRH1ADORA3HTR2AHTR7
SCHEMBL5714329 0.88 SIGMAR1 (0.48) HRH2HRH1ADORA3HTR2AHTR7
SCHEMBL5714798 0.88 SIGMAR1 (0.47) HRH2HRH1ADORA3HTR2AHTR7
SCHEMBL5715097 0.87 HTR2A (0.52) HRH2HRH1ADORA3HTR2AHTR7
SCHEMBL5714939 0.86 SIGMAR1 (0.46) ADORA3HTR2AHTR7OPRM1SIGMAR1
SCHEMBL5714910 0.85 DRD2 (0.49) POLBDRD3
SCHEMBL5714867 0.85 SIGMAR1 (0.44) HRH2HRH1ADORA3HTR2AHTR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2006527212-A 2006-11-30 JP claimed
US-20060160820-A1 Substituted piperazine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US claimed
EP-1636187-A1 SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP claimed
WO-2004111004-A1 SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO claimed
US-20060160820-A1 Substituted piperazine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US disclosed
EP-1636187-A1 SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP disclosed
WO-2004111004-A1 SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160820-A1 Substituted piperazine carbamates LIPE, PNLIP, LPL HRH2 589/4885HRH1 602/4885ADORA3 3862/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.